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Leber congenital amaurosis (LCA) is the earliest and most severe form of all inherited retinal dystrophies,
responsible for congenital blindness. Disease-associated mutations have been hitherto reported in seven genes.
These genes are all expressed preferentially in the photoreceptor cells or the retinal pigment epithelium but they
are involved in strikingly different physiologic pathways resulting in an unforeseeable physiopathologic variety.
This wide genetic and physiologic heterogeneity that could largely increase in the coming years, hinders the
molecular diagnosis in LCA patients. The genotyping is, however, required to establish genetically defined
subgroups of patients ready for therapy. Here, we report a comprehensive mutational analysis of the all known
genes in 179 unrelated LCA patients, including 52 familial and 127 sporadic (27/127 consanguineous) cases.
Mutations were identified in 47.5% patients. GUCY2D appeared to account for most LCA cases of our series
(21.2%), followed by CRB1 (10%), RPE65 (6.1%), RPGRIP1 (4.5%), AIPL1 (3.4%), TULP1 (1.7%), and
CRX (0.6%). The clinical history of all patients with mutations was carefully revisited to search for phenotype
variations. Sound genotype–phenotype correlations were found that allowed us to divide patients into two main
groups. The first one includes patients whose symptoms fit the traditional definition of LCA, i.e., congenital or
very early cone-rod dystrophy, while the second group gathers patients affected with severe yet progressive rod-
cone dystrophy. Besides, objective ophthalmologic data allowed us to subdivide each group into two subtypes.
Based on these findings, we have drawn decisional flowcharts directing the molecular analysis of LCA genes in a
given case. These flowcharts will hopefully lighten the heavy task of genotyping new patients but only if one has
access to the most precise clinical history since birth. Hum Mutat 23:306–317, 2004 r 2004 Wiley-Liss, Inc.
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DATABASE:
Multigenic disorder: LCA – OMIM: 204000
INTRODUCTION
Originally described by Theodore Leber in 1869, Leber
congenital amaurosis (LCA; MIM# 204000) is the earliest
and most severe form of all hereditary retinal dystrophies,
responsible for congenital blindness [Leber, 1869]. The
diagnosis is usually made at birth or during the first
months of life in an infant with total blindness or greatly
impaired vision, normal fundus, and non-recordable
electroretinogram (ERG) [Franceschetti and Dieterle,
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1954]. It was usually accepted that LCA accounted for
5% of all inherited retinal dystrophies [Kaplan et al.,
1990]. Nevertheless, this frequency is underestimated
because it is now admitted that in some cases LCA could
represent the extreme end of a spectrum of severity of
retinal dystrophies [Perrault et al., 2000; Lorenz et al.,
2000]. Hitherto, LCA was considered as an autosomal
recessive genetically heterogeneous condition. Ten LCA
genes have been so far identified or mapped, namely: 1)
the retinal specific guanylate cyclase gene (GUCY2D;
retGC1; MIM# 600179) at the LCA1 locus (17p13.1)
[Perrault et al., 1996], 2) the gene encoding the 65-kD
protein specific to the retinal pigment epithelium
(RPE65; MIM# 180069) at the LCA2 locus (1p31)
[Marlhens et al., 1997; Perrault et al., 1999], 3) the
cone-rod homeobox-containing gene (CRX, 19q13.3;
MIM# 602225 [Freund et al., 1998; Jacobson et al.,
1998; Swaroop et al., 1999], 4) the gene encoding the
arylhydrocarbon receptor interacting protein-like 1
(AIPL1; MIM# 604392) at the LCA4 locus (17p13.1)
[Sohocki et al., 2000a], 5) the gene encoding the
retinitis pigmentosa GTPase regulator-interacting protein
1 (RPGRIP1; MIM# 605446) at the LCA6 locus
(14q11) [Dryja et al., 2001; Gerber et al., 2001], 6)
the human homologue of the Drosophila melanogaster
crumbs gene (CRB1, 1q31; MIM# 604210) [Lotery
et al., 2001; den Hollander et al., 2001; Gerber et al.,
2002], 7) the gene encoding the tubby-like protein 1
(TULP1, 6q21.3; MIM# 602280) [North et al., 1997],
8) LCA3 (MIM# 604232) on chromosome 14q24
[Stockton et al., 1998], 9) LCA5 (MIM# 604537) on
chromosome 6q11-16 [Dharmaraj et al., 2000], and 10)
LCA9 on chromosome 1p36 [Keen et al., 2003]. The last
three loci, respectively, account for the disease in a
consanguineous Saudi Arabian LCA family, a multi-
generational kindred of Old Order River Brethren, an
isolate hailing from Swiss immigrants to America in the
1750s [Stockton et al., 1998; Dharmaraj et al., 2000],
and finally a consanguineous family of Pakistani origin
[Keen et al., 2003]. All together, these genes are
consistent with autosomal recessive inheritance in the
vast majority of cases.
However, some exceptional autosomal dominant
forms of LCA associated with heterozygote mutations
of the CRX gene have been reported [Tzekov et al.,
2001; Perrault et al., 2003]. Interestingly, all LCA
genes hitherto identified are involved in strikingly
different physiologic pathways resulting in an unfore-
seeable physiopathologic variety. This outstanding
genetic and physiologic diversity that could largely
increase in the coming years already hinders the
molecular diagnosis in LCA patients. Sound pheno-
type–genotype correlations are required to lighten the
task of molecular biologists, in guiding genetic studies in
a new patient, and to anticipate the final outcome in a
blind infant.
Here, we report the comprehensive mutation analysis
of known LCA genes in a cohort of 179 unrelated LCA
patients and the identification of sound phenotype–
genotype correlations allowing us to draw decisional




A total of 179 unrelated patients were either seen at the
Ophthalmo-genetic Center of Necker Enfants-Malades Hospital
or sent to the laboratory by referent ophthalmologists or geneticists
from France or other countries worldwide.
Our inclusion criteria were: 1) severe impairment of visual
function detected at birth or during the first months of life with
pendular nystagmus, roving eye movements, eye poking, inability
to follow light or objects, and normal fundus; 2) extinguished
ERG; and 3) exclusion of ophthalmological or systemic diseases
sharing features with LCA. Detailed clinical data were required for
each patient, i.e., 1) age and mode of onset, 2) light behavior since
birth, 3) natural history of the visual impairment since the first
months of life including the subjective impressions of parents, 4)
refraction data, 5) ophthalmologic findings (anterior chamber and
fundus), 6) visual acuity (if measurable), and 7) electrophysiology
recordings. The course of the disease was determined by
interviewing the patients or their parents, and a pedigree was
established. Among the 179 families, 52 were multiplex (26
consanguineous) and 127 were simplex cases (27 consanguineous).
These data, as well as the origin of the families, are shown in Table 1.
Genomic DNA was extracted from whole blood or immortalized
lymphoblast cell lines of patients using standard methods. When a
mutation was identified, we examined the parents and other family
members when available in both sporadic and familial cases.
Control Panel
Genomic DNA obtained from 96 unrelated healthy individuals
were used as a control panel for molecular studies.
LinkageAnalysis of LCA Loci
For the 10 hitherto identified LCA loci, fluorescent primers
flanking markers containing short tracks of di-, tri-, tetra-, or
pentanucleotide repeats were either chosen from the Ge´ne´thon
Linkage Map [Dib et al., 1996] or designed from the Working
Draft of the Human Genome available at UCSC (Supplementary
Table S1, available online at http://www.mrw.interscience.wiley.
com/suppmat/1059-7794/suppmat/). In addition, primers flanking
intragenic polymorphic markers were designed from the AIPL1,
CRX, CRB1, RPGRIP1, and RPE65 sequences, respectively
(Supplementary Table S1). Amplified fragments were electrophor-
esed on an automatic sequencer (ABI 3100, Applied Biosystems,
Foster City, CA) and analyzed using the GeneScan Analysis 3.7
and Genotyper softwares.
For each marker, the heterozygote frequency and the size range
of alleles were either available from Ge´ne´thon Linkage Map [Dib
et al., 1996] or determined by the study of 50 control individuals
(100 chromosomes, see Supplementary Table S1).
Mutational Screening of LCAGenes
Mutational screening of the seven LCA genes (GUCY2D,
RPE65, CRX, AIPL1, RPGRIP1, TULP1, and CRB1) was
performed on genomic DNA from the patients using primers
designed to flank the splice junctions of each coding exon
(Supplementary Table S2A-G, available online at http://
www.mrw.interscience.wiley.com/suppmat/1059-7794/suppmat/).
After standard PCR amplification (conditions available on
request), products were screened for mutations using denaturing
high-pressure liquid chromatography (DHPLC). Heteroduplex
formation was induced by heat denaturation of PCR products at
941C for 10 min, followed by gradual reannealing from 941C to
251C over 30 min. DHPLC analysis was performed with the
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WAVE DNA fragment analysis system (Transgenomic, Cheshire,
UK). PCR products were eluted at a flow rate of 0.9 ml/min with a
linear acetonitrile gradient. The values of the buffer gradients
(buffer A, 0.1 M triethylammoniumacetate; buffer B, 0.1 M
triethylammoniumacetate/25% acetonitrile), start and end points
of the gradient, and melting temperature predictions were
determined by the WAVEMAKER software (Transgenomic,
Cheshire, UK). Optimal run temperatures were empirically
determined. Mobile-phase temperatures were assessed within a
51C window above and below the suggested run temperature on
the basis of each fragment’s characteristic melting profile.
PCR fragments displaying DHPLC abnormal profiles were
further sequenced using the Big Dye Terminator Cycle Sequencing
Kit v2 (ABI Prism, Applied Biosystems, Foster City, CA on a 3100
automated sequencer).
Mutation Nomenclature
We have chosen to number the A of the start codon (ATG) of
the GenBank cDNA sequences as nucleotide +1 for the genes as
follows: GUCY2D, NM_000180; RPE65, NM_000329; CRX,
NM_000554; AIPL1, NM_014336; RPGRIP1, NM_020366,
CRB1, NM_012076, TULP1, NM_003322.
RESULTS
Markers for Linkage Study of the10 LCA Loci
In addition to available AFM markers [Dib et al.,
1996], we have designed new microsatellite markers
either intragenic (n = 4), RPE65, AIPL1, CRB1, and
RPGRIP1, or extragenic (n = 4) flanking the GUCY2D,
RPE65, CRX and TULP1 gene (Supplementary Table S1).
The percentage of heterozygosity of designed markers
has been calculated by studying 100 chromosomes of
diverse geographical origins. All markers but one were
highly informative (>71%, see Supplementary Table S1).
Spectrum of Mutations of the Seven LCAGenes
A total of 179 unrelated LCA patients, 52 familial (26
consanguineous), and 127 sporadic cases (27 consangui-
neous) were studied. The linkage status of all familial
cases and sporadic consanguineous cases was determined
using two flanking markers and, when available, an
intragenic marker, specific to the 10 LCA loci,
respectively. Hints of linkage allowed us to direct the
mutational screening of LCA genes in only 13 of 52
familial cases and 6 of 27 consanguineous sporadic cases.
For the remaining families and the non-consanguineous
sporadic cases, all known genes were screened for
mutations.
A total of 85 of 179 (27 familial, 17 consan-
guineous sporadic, 42 sporadic) were found to carry
mutations in one of the seven LCA genes. The respective
frequencies of mutations in each gene were, in decreasing
order: GUCY2D 21.2% (38/179 families), CRB1 10%
(18/179 families), RPE65 6.1% (11/179 families),
RPGRIP1 4.5% (8/179 families), AIPL1 3.4% (6/179
families), TULP1 1.7% (3/179 families), and CRX
0.6% (1/179 families). All patients but eight were found
to be either homozygote for the mutation or compound
heterozygote. Mutations are described for each gene in
Table 2A–G and graphically in Supplementary Figure
S1A–G (available online at http://www.mrw.interscience
.wiley.com/suppmat/1059-7794/suppmat/).
GUCY2D (Table 2A, Supplementary Figure S1A).
Seventy-five GUCY2D disease-associated mutations
were identified in 38 patients with LCA (75/76 disease
alleles). A total of 21 patients were found to carry two
null GUCY2D alleles (20 homozygous), five patients
carried a null allele and a missense mutation, 10 patients
harbored two missense mutations (nine homozygous),
and one patient was homozygous for an inframe
duplication of 48 bp.
Thirty-four different GUCY2D mutations were found.
Missense mutations make up the majority (16/34),
followed by splice and frameshift mutations (7/34,
TABLE 1.Origin andGenealogy of LCA Familiesn
Simplex Multiplex
Origin Consanguineous Non-consanguineous Consanguineous Non-consanguineous
France 4 60 2 22



















Total 27 100 26 26
nFor each country, the numeric data indicate the number of unrelated families of each genetic type.
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respectively), nonsense mutations (3/34), and one
inframe duplication. Five of these mutations are novel,
while 29 have been reported previously [Perrault et al.,
1996; El-Shanti H et al., 1999; Lorenz et al., 2000;
Perrault et al., 2000; Rozet et al., 2001; Hanein et al.,
2002; Lotery et al., 2003].
Five different alleles account for 36 of the 75 identified
disease alleles (47.3%): 1) the c.387delC mutation was
found in a homozygous state in seven unrelated patients,
all born to consanguineous parents hailing from North
Africa; 2) the c.2943delG deletion was identified in five
unrelated patients of Finnish origin (four homozygotes)
suggesting a founder effect [Hanein et al., 2002]; 3) the
p.Phe565Ser missense mutation was found to homo-
zygously segregate in three unrelated patients of three
Algerian families; 4) the c.620delC mutation was
identified in two apparently unrelated consanguineous
Northern African families; and finally, 5) the p.Ser448X
nonsense mutation concerned two unrelated families
(one consanguineous) hailing from Italy and Portugal,
respectively.
The majority of disease alleles identified in the
GUCY2D group of LCA patients are predicted to be
null alleles (47/79, 61.8%).
Most mutations were located in exon 2 (n = 9, 17
families), exon 17 (n = 4, four families), exon 15 (n = 3,
seven families), and intron 9 (n = 3, three families). No
mutations were found in exons 5, 6, 10, 11, 13–15, 18,
and 19 (Supplementary Figure S1).
RPE65 mutations (Table 2B, Supplementary Figure
S1B). Nineteen RPE65 disease alleles were found in 11
unrelated patients (19/22 disease alleles). Four patients
harbored a null mutation on each RPE65 allele (two
homozygotes, two compound heterozygotes). Three other
patients carried two missense mutations (two homozygotes,
one compound heterozygote). One patient carried a null
mutation on an allele and a missense mutation on the other.
Finally, in three patients, only one disease-associated mutation
was found (two null and one missense, respectively).
The 16 different RPE65 mutations identified in our
series included two nonsense mutations, two one- or
two-base pairs deletions, five splice site mutations, and
seven missense mutations; none was recurrent. Three of
these mutations are new, while 12 have been reported
previously [Marlhens et al., 1997; Gu et al., 1997;
Morimura et al., 1998; Perrault et al., 1999; Simovich
et al., 2001].
The mutations were found to be relatively homo-
geneously spared throughout the sequence.
CRX mutations (Table 2C, Supplementary Figure
S1C). A heterozygous CRX 1bp deletion (c.510delT)
was found to segregate through two generations in a
family affected with true autosomal dominant LCA
[Perrault et al., 2003]. This mutation located in the third
exon of the gene led to the apparition of a premature
stop codon and the truncation of three important protein
domains, including the OTX tail [Perrault et al., 2003].
AIPL1 mutations (Table 2D, Supplementary Figure
S1D). In 6 of 179 unrelated patients with LCA, 12
disease-associated alleles were identified. Four patients
were found to carry a null mutation deleting the hinge
domain on each AIPL1 allele. Indeed, the p.Trp278X
mutation was found to be homozygous in three simplex
patients born to non-consanguineous parents hailing
from France (n = 2/3) and Spain (1/3), respectively. In a
fourth non-consanguineous family, this same mutation
was found to be associated in patients with a splice-site
mutation (c.277–2A>G).
In addition, two patients were found to be homozygous
for a missense mutation converting an amino acid of one
class into an amino acid of another class. The p.Val71Phe
mutation was identified in a non-consanguineous
simplex case while the pAla197Pro mutation was found
to segregate in a consanguineous LCA family originating
from North Africa.
Three of the four different AIPL1 mutations described
here, including the recurrent p.Trp278X mutation (7/12
disease alleles, 58%), have already been reported
elsewhere [Sohocki et al., 2000].
RPGRIP1 mutations (Table 2E, Supplementary Figure
S1E). Twelve RPGRIP1 disease alleles were found in 8
of 179 unrelated LCA patients Among these patients,
2 of 8 carried homozygous mutations (2 of 2 familial
consanguineous), 2 of 8 were compound heterozygotes (2
of 2 simplex non-consanguineous), and four were single
heterozygotes (4 of 4 simplex non-consanguineous).
A total of 10 different mutations were found, all but
one being null alleles: four small frameshift insertions or
deletions, two splice mutations, and three nonsense
mutations. All nine mutations are expected to delete the
RPGR interacting domain. Only one missense mutation
converting a conserved uncharged amino acid into an
acidic amino acid was found in a patient born to
consanguineous parents hailing from Morocco
(p.Gly746Glu). This amino acid is conserved in murine
and bovine sequences and lies in the coiled–coiled
domain of the protein. Of the 10 different RPGRIP1
mutations, three are novel and seven have already been
reported [Dryja et al., 2001; Gerber et al., 2001].
CRB1 mutations (Table 2F, Supplementary Figure
S1F). In 18 of 179 unrelated LCA patients, 36 disease-
associated mutations were found. Nine of these 18
patients were found to be homozygote for null alleles (n
= 4, three sporadic) or missense mutations (n = 5, three
sporadic). The nine others patients were either com-
pound heterozygotes for a null mutation and a missense
mutation (n=5, five sporadic), or two missense muta-
tions (n = 4, eight sporadic).
A total of 21 different CRB1 mutations were found
including three nonsense mutations, five frameshift
microdeletions, one splice mutation, and 12 missense
mutations. Ten of these mutations are novel while 11
have already been reported [Lotery et al., 2001; den
Hollander et al., 2001; Gerber et al., 2002]. All
mutations but one were scattered over exons 6 to 12.
Three different mutations were found in more than
one family. The p.Cys948Tyr missense mutation was
identified in three French simplex cases. One of them,
born to consanguineous parents, harbored the mutation
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TABLE 2.
Family Exon Base change Allele1predicted change Exon Base change Allele 2 predicted change
A.GUCY2DMutations in Patients A¡ectedWith LCAw
3 Fn 2 c.387delC p.Asn129fsX1651,2,3 2 c.387delC p.Asn129fsX1651,2,3
7 Fn 8 c.1694T4C p.Phe565Ser2 8 c.1694T4C p.Phe565Ser2
11Sn 2 c.3G4C p.Met1?2 2 c.3G4C p.Met1?2
17 Fn 8 c.1694T4C p.Phe565Ser2 8 c.1694T4C p.Phe565Ser2
20 Sn 9 c.1805_1829del p.Arg602fsX6362 9 c.1805_1829del p.Arg602fsX6362
23 Fn 2 c.620delC p.Ala207fsX2151,2 2 c.620delC p.Ala207fsX2151,2
31Sn 15 c.2927G4T p.Arg976Leu2 15 c.2927G4T p.Arg976Leu2
33 Sn 17 c.3078_3079delGA p.Gly1026fsX10712 17 c.3078_3079delGA p.Gly1026fsX10712
34 Sn 2 c.620delC p.Ala207fsX2151,2 2 c.620delC p.Ala207fsX2151,2
36 Sn 8 c.1694T4C p.Phe565Ser2 8 c.1694T4C p.Phe565Ser2
51F 2 c.3G4A p.Met1?2 Intron 9 c.1957-1G4T2 Aberrant splicing
52 S 3 c.937C4T p.Arg313Cys2 4 c.1343C4A p.Ser448X2
56 Sn 17 c.3956A4C p.His1019Pro 17 c.3956A4C p.His1019Pro2
70 Sn Intron 9 c.1956+2T4A2 Aberrant splicing Intron 9 c.1956+2T4A Aberrant splicing
72 S 17 c.3106C4T p.Gln1036X2 17 c.3106C4T p.Gln1036X2
76 F 4 c.1052A4G p.Tyr351Cys4 4 c.1052A4G p.Tyr351Cys4
82 S 2 c.387C4A p.Asn129Lys2 16 c.2983C4T p.Arg995Trp2
85 Sn 2 c.52_99dup p.Gly18_Leu33dup2 2 c.52_99dup p.Gly18_Leu33dup2
88 S 16 c.3025A4T p.Met1009Leu2 Intron 9 c.1957-1G4T2 Aberrant splicing
89 F 2 c.121C4T p.Leu41Phe2 2 c.121C4T p.Leu41Phe2
90 Fn 2 c.387delC p.Asn129fsX1651,2,3 2 c.387delC p.Asn129fsX1651,2,3
91Fn 2 c.387delC p.Asn129fsX1651,2,3 2 c.387delC p.Asn129fsX1651,2,3
110 Sn 2 c.226_239del PAla76fsX842 2 c.226_239del pAla76fsX842
113 S 4 c.1343C4A p.Ser448X2 4 c.1343C4A p.Ser448X2
117 S 7 c.1618C4T p.Arg540Cys2 ‘‘?’’ ‘‘?’’
121Sn 2 c.387delC p.Asn129fsX1651,2,3 2 c.387delC p.Asn129fsX1651,2,3
129 S 2 c.387delC p.Asn129fsX1651,2,3 2 c.387delC p.Asn129fsX1651,2,3
134 S Intron 7 c.1566+2T4C Aberrant splicing 2 c.2T4A p.Met1?2
138 S Intron16 c.3043+4A4T Aberrant splicing 15 c.2943delG p.Ser981fsX10715
139 Sn 17 c.3118C4T p.Arg1040X 17 c.3118C4T p.Arg1040X
147 F 15 c.2943delG p.Ser981fsX10715 15 c.2943delG p.Ser981fsX10715
148 S 15 c.2943delG p.Ser981fsX10715 15 c.2943delG p.Ser981fsX10715
155 S 12 c.20302C4T PArg768Trp 2 c.87_88insC p.Pro30fsX3182
165 Sn 2 c.387delC p.Asn129fsX1651,2,3 2 c.387delC p.Asn129fsX1652,3
170 Sn 2 c.387delC p.Asn129fsX1651,2,3 2 c.387delC p.Asn129fsX1652,3
171Sn 15 c.2800G4C p.Ala934Pro 15 c.2800G4C p.Ala934Pro
196 S 15 c.2943delG p.Ser981fsX10715 15 c.2943delG p.Ser981fsX10715
257 S 15 c.2943delG p.Ser981fsX10715 15 c.2943delG p.Ser981fsX10715
B. RPE65 Mutations in Patients A¡ectedWith LCAw
1Fn Intron1 c.11+5G4A Aberrant splicing Intron1 c.11+5G4A6 Aberrant splicing
8 F Intron 8 c.912+1G4A6 Aberrant splicing ‘‘?’’ ‘‘?’’
16 F 7 c.700C4T p.Arg234X6 10 c.1060delA p.Lys354fsX3726
29 S 10 c.1087C4A p.Pro363The6,7 13 c.1418T4A p.Val473Asp8
54 Sn 3 c.190C4T p.Gln64X6 3 c.190C4T p.Gln64X6
95 S 12 c.1031T4C p.Ala434Val6 ‘‘?’’ ‘‘?’’
114 Sn 9 c.989G4A p.Cys330Tyr6 9 c.989G4A p.Cys330Tyr6
122 Fn Intron 2 c.94-2A4T Aberrant splicing Intron 2 c.94-2A4T Aberrant splicing
128 S 6 c.544C4A p.His182Asn8 Intron 6 c.644-2A4T8 Aberrant splicing
182 F 3 c.131G4A p.Arg44Gln9 5 c.444G4T p.Glu148Asp
213 F 6 c.615_616delCA p.Asn205fsX233 ‘‘?’’ ‘‘?’’
C.CRXMutations in Patients A¡ectedWith LCAw
22 F 3 c.510delT p.Pro170fsX52610
D. AIPL1Mutations in Patients A¡ectedwith LCAw
6 S 6 c.834G4A p.Trp278X11 6 c.834G4A p.Trp278X11
24 F 6 c.834G4A p.Trp278X11 Intron 2 c.277-2A4G Aberrant splicing
26 Fn 4 c.589G4C p.Ala197Pro 4 c.589G4C p.Ala197Pro
115 S 6 c.834G4A p.Trp278X11 6 c.834G4A p.Trp278X11
149 S 6 c.834G4A p.Trp278X11 6 c.834G4A p.Trp278X11
166 S 2 c.211G4T p.Val71Phe 2 c.211G4T p.Val71Phe
wMutations of a) GUCY2D, b) RPE65, c)CRX, d) AIPL1, e) RPGRIP1, f) CRB1, and g) TULP1 identi¢ed in our panel of LCA families. Asterisks indicate
consanguinity of the parents of LCA patients. S, sporadic case; F, familial case.The A of the start codon (ATG) of the GenBank cDNA sequences is
nucleotide +1 for the genes as follows: GUCY2D, NM_000180; RPE65, NM_000329; CRX, NM_000554; AIPL1, NM_014336; RPGRIP1, NM_020366,
CRB1, NM_012076;TULP1, NM_003322.
References:1Perrault et al. [1996]; 2Perrault et al. [2000]; Lorenzet al. [2000]; 3Rozet et al. [2001]; 4Loteryet al. [2003]; 5Haneinet al. [2002]; 6Marlhens
et al. [1997]; Perrault et al. [1999];7Guet al. [1997]; 8Lorenzet al. [2000]; 9Simovichet al. [2001];10Perrault et al. [2003];11Sohocki et al. [2000];12Dryja
et al. [2001];Gerber et al. [2001]; 13Lotery et al. [2001]; 14denHollander et al. [2001]; 15Gerber et al. [2002].
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homozygously. In the other two, the p.Cys948Tyr
mutation was found to be associated to an other
missense mutation (p.Cys1321Gly) and a null allele
(c.613_619del), respectively. The p.Leu1107Pro muta-
tion was found to be homozygous in one patient and
associated to the p.Ser1025Ile missense mutation in
another one, both being French non-consanguineous
simplex cases. This latter mutation was also found to be
associated with the p.The745Met mutation in an other
French simplex patient.
TULP1 mutations (Table 2G, Supplementary Figure
S1G). Six disease alleles were identified in 3 of 179
unrelated patients. One patient, belonging to multiplex
family originating from Italy, was found to carry a splice
mutation (c.99+1G>A) and a nonsense mutation
(p.Glu402X). The other two, born to consanguineous
parents (one simplex), were homozygous for a missense
mutation (p.Arg400Trp, pGly368Trp, respectively). Both
missense mutations concern conserved amino acids lying
in the very conserved C-terminal region of the TUB
family, including TUB and TULP2 [North et al., 1997].
The four different TULP1 mutations identified in our
series have not been reported earlier.
Phenotype^genotype correlations. All patients in-
cluded in this study fulfilled strict inclusion criteria for
diagnosis of LCA, i.e., congenital nystagmus, no or very
poor ocular pursuit, digito-ocular signs of Franceschetti
attesting of profoundly impaired vision, and no record-
able ERG since birth or the first months of life. For the
vast majority of patients, the screening of all seven LCA
genes has been randomly undertaken, especially as the
severity of the disease in the early beginning of life
appeared to be sufficient to assert the diagnosis of LCA.
Among the 179 LCA families belonging to our series, at
least one disease-causing mutation was found in one of
the seven LCA genes in 85 patients. For each of these
patients, the clinical history was strictly revisited by
questioning themselves when adults or their parents
when younger. When necessary and possible, an
ophthalmoscopic examination as well as refraction
measurements were performed. The visual field was
recorded when the visual acuity allowed it. Brought up to
date, these clinical data resulted in the division of LCA
patients into two groups on the basis of their light
behavior during the two first years of life. Indeed, the
patients mainly displayed either photophobia or night
blindness. In the group of patients complaining of
photophobia, hypermetropia was constantly noted as
well as severe involvement of both types of photo-
receptor cells leading to early peripheral and macular
degeneration of the retina with bone spicule pigments in
the periphery, retinal atrophy including the macular
region, very thin vessels, and optic disc pallor. When the
hypermetropia was very severe, higher than +7, the
TABLE 2.(Continued)
Family Exon Base change Allele1predicted change Exon Base change Allele 2 predicted change
E. RPGRIP1Mutations in Patients A¡ectedWith LCAw
4 Fn 15 c.2237G4A p.Gly746Glu12 15 c.2237G4A p.Gly746Glu12
9 S Intron 8 c.490+3A4G12 Aberrant splicing ‘‘?’’ ‘‘?’’
46 S 12 c.1501_1502insTGTC p.Leu501fsX50812 ‘‘?’’ ‘‘?’’
77 S 16 c.2534C4T p.Arg852X intron16 c.2710+1G4A Aberrant splicing
104 Fn 4 c.510delT p.Tyr170fsX18912 4 c.510delT p.Tyr170fsX18912
126 S 21 c.3341A4G p.Asp1114Gly 16 c.2668C4T p.Arg890X
160 S 12 c.1525C4T p.Gln509X12 ‘‘?’’ ‘‘?’’
167 S 16 c.2576_2577insTT p.Ser858fsX86512 23 c.3629_3630insG p.The1210fsX121412
F.CRB1mutations in Patients A¡ectedWith LCAw
2 Fn 6 c.2128G4C p.Glu710Gln13 6 c.2128G4C p.Glu710Gln13
2.1F 9 c.3320T4G p.Leu1107Arg13 9 c.3320T4G p.Leu1107Arg13
2.2 F 9 c.3320T4G p.Leu1107Arg 13 6 c.2128G4C p.Glu710Gln13
14 S 9 c.3320T4G p.Leu1107Arg13 9 c.3320T4G p.Leu1107Arg13
41Sn 9 c.2843G4A p.Cys948Tyr13,14 9 c.2843G4A p.Cys948Tyr13,14
42 S 8 c.2688T4A p.Cys896X14 8 c.2688T4A p.Cys896X14
54.1S 9 c.2843G4T p.Cys948Tyr 11 c.3961T4A p.Cys1321Gly
80 Fn 12 c.4121_4130del p.Arg1374fsX139715 12 c.4121_4130del p.Arg1374fsX139715
124 S 9 c.2853_2854insT p.Ala952fsX972 9 c.2853_2854insT p.Ala952fsX972
131S 7 c.2222T4C p.Met741Thr13 11 c.3988delG p.Glu1330fsX1340
154 S 9 c.3307G4A p.Gly1103Arg 9 c.3345delT p.Gly1115fsX1140
161S 7 c.2234C4T p.Thr745Met15 9 c.3074G4T p.Ser1025Ile15
163 S 7 c.2555T4C p.Ile852Thr15 Intron11 c.4005+1G4A Aberrant splicing
164 S 9 c.3074G4T p.Ser1025Ile15 9 c.3320T4C p.Leul107Pro15
187 S 2 c.613_619delTAGGAAG p.Ile205fsX219 9 c.2843G4A p.Cys948Tyr15,16
200 Sn 6 c.1750G4T p.Asp584Tyr 6 c.1750G4T p.Asp584Tyr
202 Sn 11 c.3879G4A p.Trp1293X 11 c.3879G4A p.Trp1293X
206 S 7 c.2290C4T p.Arg764Cys16 7 c.2479G4T p.Gly827X
G.TULP1Mutations in Patients A¡ectedWith LCAw
57 Sn 12 c.1198C4T p.Arg400Trp 12 c.1198C4T p.Arg400Trp
75 F Intron2 c.99+1G4A Aberrant splicing 12 c.1204G4T p.Glu402X
240 Fn 11 c.1102G4T p.Gly368Trp 11 c.1102G4T p.Gly368Trp
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visual acuity was reduced to counting fingers (CF) or
light perception (LP). In these cases, the disease is not
progressive and is pathognomonic of GUCY2D muta-
tions [Perrault et al., 1996]. When the hypermetropia
was lower than +7, the visual acuity was frequently
countable and ranged from CF and 1/20. These data, as
well as the presence of a keratoconus, suggest mutations
in the AIPL1 or RPGRIP1 genes. In this first group of
patients, the disease comes in the form of congenital or
very early cone-rod dystrophy with dramatic and
invariable cone dysfunction (Fig. 1).
In the second group of patients complaining from
night blindness, two clinical subtypes can be distin-
guished, one with hypermetropia and the second without
hypermetropia.
In the first subtype, an early macular reorganization is
almost constantly visible at the fundus examination.
Consequently, a central scotoma is noted at the visual
field and the visual acuity ranges from 1/10 to 2/10 in the
first decade of life. These clinical findings suggest
mutations in either CRB1 or CRX. In the second
subtype, an early peripheral involvement of the retina is
visible at the fundus examination giving an early aspect
of retinitis pigmentosa. The visual field confirms this
aspect and shows a progressive concentric reduction. The
visual acuity is much better than in other groups of
patients, especially during daytime, reaching values
ranging from 1/10 to 2/10 or better during the first
decade. This ‘‘moderate’’ form of LCA strongly suggests
mutations in RPE65 or TULP1 genes.
In this second group of patients, the disease comes in
the form of a severe yet progressive rod-cone dystrophy,
still different from the stationary cone-rod dystrophy of
the first group of patients (Fig. 1).
DISCUSSION
The genetic heterogeneity of Leber congenital
amaurosis has been accepted for a long time [Warden-
burg et al., 1963] but it turned out to be largely higher
than all odds. So far, 10 genes have been mapped on
human chromosomes and seven identified. One of the
aims of the present study was to determine the
prevalence of each genetic subtype by genotyping 179
unrelated LCA patients hailing from countries world-
wide. Mutations were identified in 85 of 179 patients
(47.5%). GUCY2D mutations appeared to account for
most of the LCA in our series (21.2%), followed by CRB1
(10%), RPE65 (6.1%), RPGRIP1 (4.5%), AIPL1 (3.4%),
TULP1 (1.7%), and CRX (0.6%).
This wide genetic heterogeneity raises a problem of
genetic counseling in couples of LCA patients who wish
to have children. Indeed, in these situations, the risk for
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FIGURE 1. Clinical £owchart. LCA and early onset retinitis pigmentosa are divided on the basis of light behavior, the refraction data,
the aspect of the retina, and the visual acuity (VA). CF, counting ¢ngers; LP, light perception.This £owchart allows one to direct the
molecular analysis of selected LCA genes.
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100% (same gene). The identification of the disease-
causing gene is of great help to solve these ambiguities.
From this point view, it is worth noting that in our series
are included three families with both parents affected
with LCA (Fig. 3). In the first two families, patients were
studied before they married (Fig. 3A and B). In the first
one, the woman carried a homozygous mutation in the
GUCY2D gene (p.Phe565Ser) while her husband
harbored a homozygous mutation in the RPGRIP1 gene
(p.Gly746Glu). They were informed of absence of risk for
descent and, indeed, they gave birth to two healthy
children (Fig. 3A). In the second family, the woman
carried compound heterozygote mutations in the GU-
CY2D gene (p.Met1Ile, c.1957–1G>T). All genes were
screened in her husband but no mutation was found.
Again, an encouraging genetic counseling was given and,
indeed, they gave birth to two healthy children (Fig. 3B).
The third family was included in our series after the birth
of two children. Both parents were unrelated but were
born to consanguineous parents and were affected with
LCA. No genetic counseling was done and the diagnosis
of LCA was carried in the first child because his mother
was already pregnant for the second time. Both children
are affected with LCA. Both parents were found to carry
different homozygous mutation in the CRB1 gene
(p.Glu710Gln and p.Leu1107Arg respectively) and both
children harbored compound heterozygote mutations
(Fig. 3C).
Interestingly, 38% of the patients of our series
originate from Mediterranean countries (68/179, Table
1). Among them, 27 (39.7%) harbored a mutation in the
GUCY2D gene. This might explain that in our panel, the
proportion of patients harboring GUCY2D mutations is
higher than in other series [Lotery et al., 2003]. This
situation is comparable to that met for the rhodopsine
gene in which the p.Pro23His mutation is prevalent in
the United States (12% of American autosomal
dominant retinitis pigmentosa) [Dryja et al., 1990; Farrar
et al., 1990] but not in Europe.
A wide allelic heterogeneity was found for all genes;
however, some recurrent mutations were identified. For
example, in the Mediterranean geographic subgroup,
three distinct recurrent mutations were found in
apparently unrelated families hailing from Maghreb,
suggesting the existence of founder effects in North
Africa (c.387delC, c.620delC, p.Ser448X).
Along the same lines, four unrelated families of
Finnish origin were found to carry the same c.2943delG
mutation not found in patients hailing from other
countries worldwide [Hanein et al., 2002].
For more than half the patients of our series, the
disease gene remains to be identified. In our hands,
genome-wide search for homozygosity in large multiplex
consanguineous families unlinked to any of the 10 LCA
loci failed to identify a major locus. Subsequently, it is
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FIGURE 2. Decision-making £owchart for themolecular diagnosis of LCA.The study of patients a¡ectedwith LCAcould bedividedon
the basis of the clinical history of the disease, the existence of consanguinity, the primary mapping of the disease-locus, and the
molecular screening of the gene of interest.
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of them accounting for a small proportion of patients
(unpublished results).
Whatever the gene (CRX apart), most patients (77/
85, 490%) were found to be homozygote (n = 50) or
compound heterozygotes (n = 28) for mutations. Correct
segregation of disease alleles was demonstrated in 71
cases in which family samples were available for study.
In seven unrelated patients, only one disease allele was
identified (RPGRIP1, n = 3; RPE65, n = 3; GUCY2D,
n = 1; respectively). Direct sequencing failed to identify
a disease-associated mutation on the second allele. A
possible digenism could have been considered to explain
this. However, none of these seven patients were found
to carry another mutation in one of the six other known
LCA genes. In addition, none of the three patients with
RPGRIP1 mutations were found to carry any alteration
in the RPGRIP1 protein partner, RPGR, which muta-
tions account for severe X-linked retinitis pigmentosa
[Meindl et al., 1996]. Similarly, for the three unrelated
patients with RPE65 mutations, we failed to identify any
change in the lecithin retinol acyltransferase (LRAT),
which also plays a crucial role in the retinoid cycle and in
which alterations have been shown to account [Deigner
et al., 1989], as RPE65 does, for some early-onset severe
retinal dystrophies. Besides, it is admitted that in many
recessive disorders, even with no evidence for non-allelic
heterogeneity, only about 70% of the molecular defects
can be found [Ducroq et al., 2002]. Therefore, it is likely
that the undiscovered mutations lie in unscreened regions
of the genes such as the promoter region (i.e., PAX6
[Okladnova et al., 1998a,b; Sander et al., 1999; Zheng
et al., 2001]), intronic sequences, or 30 untranslated
regions (i.e., alpha-globin [Waggoner and Liebhaber,
2003]).
Along the same lines, it is worth noting that for small
consanguineous families (one or two affected children) in
which several chromosomal regions are found to be
homozygotes, some can correspond to LCA loci. When
the screening of the associated gene fails to identify the
disease causing mutation, one cannot settle between
homozygosity by random or a mutation lying in an
unscreened region of the gene. Consequently, it is
possible that the proportion of LCA patients related to
one of the seven LCA genes will be higher than the 48%
estimated in our series.
The growing number of LCA genes leads to growing
difficulties in genotyping due to heavy time-consuming
studies. However, genotyping remains essential before
any therapeutic approach. It is why one of the only ways
to get out of this difficult situation might be the
establishment of phenotype–genotype correlations in
order to direct molecular studies in a new patient.
The screening of LCA genes in our series evidenced a
high prevalence of null alleles: (in decreasing order, CRX
non included) 83.3% in RPGRIP1, 66.7% in AIPL1,
62.7% in GUCY2D, 57.9% in RPE65, 36.1% in CRB1,
and 33.3% in TULP1. No correlation between the nature
of the mutation and the phenotype in patients could be
established within the same gene. From this point of
view, it is worth noting that 21 different CRB1 mutations
were identified in 18 patients of our series affected with a
severe phenotype corresponding to the minimal criteria
required for the diagnosis of LCA. Among these 21
mutations, three (p.Cys948Tyr, p.The745Met and





















FIGURE 3. Pedigrees and segregation of disease-causing muta-
tions in three LCA families (A, B, C, respectively) in which both
parents are a¡ectedwith LCA.
314 HANEIN ETAL.
autosomal recessive retinitis pigmentosa, characterized
by a preservation of the para-arteriolar retinal pigment
epithelium [den Hollander et al., 1999]. Nevertheless,
the mutation of the second CRB1 allele was constantly
different in the two, LCA and RP12, phenotypes.
However, in the past, a certain degree of clinical
heterogeneity has been recognized in LCA [Traboulsi and
Maumenee, 1995] but these subtle clinical differences
have been subsequently neglected. In 1999, after the
identification of the first two LCA genes, GUCY2D
[Perrault et al., 1996] and RPE65 [Marlhens et al., 1997],
we already demonstrated that mutations in these genes
led to different functional outcome of the disease [Perrault
et al., 1999]. More precisely, in a short series of 27
patients, 20 harboring mutations in GUCY2D and seven
harboring mutations in RPE65, we showed that GUCY2D
mutations were responsible for a congenital severe and
stationary cone-rod dystrophy, while RPE65 mutations
were responsible for a less severe and progressive rod-cone
dystrophy [Perrault et al., 1999; Lorenz et al., 2000].
In the present study, our series of patients harboring
mutations in one of the seven LCA genes has been
enlarged to 85 of 179 patients (47.5%). For these 85
patients, clinical data were obtained after rigorous new
examinations allowing the division of the LCA patients
into two groups according to the photoreceptor type first
involved in the disease, cones or rods. Subsequently, a
classification into four distinct clinical subtypes has been
obtained on the basis of the progression course the
disease, refraction error, the severity of the visual
deficiency, and the aspect of the retina. Each clinical
subtype is specific to one or two LCA genes. The two first
subtypes belonging to the first group of patients are
consistent with the traditional definition of LCA.
Conversely, it is in the second group of patients, and
especially in the second subtype, that the boundary
between LCA and early onset severe retinal dystrophy
(CSRD) becomes unclear, leading to the idea that in
some cases, LCA can be considered as the extreme end of
severity in the clinical spectrum of retinitis pigmentosa.
These findings allowed us to draw a clinical flowchart
to direct the molecular analysis of selected LCA genes
(Fig. 2). This flowchart is undoubtedly very helpful, as it
lightens the heavy task of genotyping in a remarkably
genetically heterogeneous condition.
In the past, linkage studies proved their power to map
disease-causing genes in genetically homogeneous or
slightly heterogeneous conditions. Conversely, in highly
heterogeneous conditions such as LCA, linkage analyses
undertaken to guide the molecular diagnosis in patients
appear to be less useful in a significant proportion of cases
despite informative markers because of the small size of
the majority of familial cases (on average two affected
sibs) and all the more so in consanguineous sporadic
cases. Indeed, in small families, genome identity can be
found by random, and in consanguineous cases, several
homozygous chromosomal regions are found. Only very
large families (four affected sibs or more) allow significant
linkage to be obtained. In fact, these indirect studies are
rather useful to exclude some loci and when several
putative localizations are possible, only the phenotype–
genotype correlations can help to select one locus more
accurately. For this reason, we have drawn a decisional
molecular diagnostic flowchart starting from the clinical
history (Fig. 2). In the future, it would be ideal to have in
all cases an informative clinical history (left part of the
flowchart). In reality, situations are more complex
because 1) in some cases, patients are too young (seen
in the first months of life); 2) in some other cases,
conversely, patients are seen too late in life and no
clinical data are available for many reasons (dead
parents, patients born in foreign countries with no
clinical files); 3) accurate clinical data are difficult to
obtain (parents refused repeated clinical examinations,
existence of lack of understanding, language difficulties.
etc.). In all three situations, the screening of all LCA
genes (guided or not by linkage studies) remains topical.
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